August 22, 2013 | Researchers evaluated the effectiveness of the ChemoFx assay by testing patients’ tumor samples for sensitivity and resistance to various chemotherapeutic agents. Patients treated with a sensitive regimen showed significant improvement in overall survival and progression-free survival. With promising results, researchers are convinced diagnostic testing could help clinicians individualize therapy in a tumor type where there are many equivalent treatment options. OncLive